Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Arzerra
(United States) [Available] ,Kesimpta
(United States) [Available]Synonyms :
Ofatumumabum, HuMax-CD20
Class :
Class: antineoplastic agents Subclass: anti-CD20 antibody
Brand Name :
Arzerra
(United States) [Available] ,Kesimpta
(United States) [Available]Synonyms :
Ofatumumabum, HuMax-CD20
Class :
Class: antineoplastic agents Subclass: anti-CD20 antibody
Dosage Forms & Strengths:Â Â
Solution for injection
20 mg per ml
100 mg per 5 ml in a vial
1000 mg per 50 ml in a vial
Chronic Lymphocytic Leukemia (Cll)Â
Previously untreated
Cycle 1: 300 mg intravenously on 1st day followed by 1000 mg 1 week later 8th day
Next 28-day cycles: 1,000 mg on 1st day for minimum 3-12 cycles until a best response is achieved
Relapsed CLL
ofatumumab is indicated in combination with cyclophosphamide and fludarabine for relapsed CLL
300 mg intravenously as 1st dose followed by 2nd dose a week later
2nd dose: 1000 mg intravenously, then
3rd dose: 1000 mg on 1st day of a subsequent 28-day cycle up to 6 cycles
Extended treatment
1st dose: 300 mg intravenously on 1st day, followed by a week later
2nd dose: 1000 mg for a week on 8th day, continued for 7 days and then
3rd dose: 1000 mg intravenously and then every 8th week for 2 years
Refractory CLL
1st dose: 300 mg intravenously, followed by the next dose a week later
2nd to 8th dose: 2000 mg intravenously every week for 7 doses
After 4 weeks: 9th to 12th dose: 4 doses of 2000 mg intravenously every 4 weeks
The total regimen contains 12 doses
Safety and efficacy are not seen in pediatrics
Refer to the adult dosing
in combination with ofatumumab, abciximab increases the risk of adverse events
in combination with ofatumumab, adalimumab increases the risk of adverse events
In combination with ofatumumab, aducanumab increases the risk of adverse events
in combination with ofatumumab, alemtuzumab increases the risk of adverse events.
in combination with ofatumumab, alirocumab increases the risk of adverse events
in combination with ofatumumab, amivantamab increases the risk of adverse events
in combination with ofatumumab, anifrolumab increases the risk of adverse events.
in combination with ofatumumab, the anthrax vaccine increases the risk of adverse events.
in combination with ofatumumab, asfotase alpha increases the risk of adverse events
in combination with ofatumumab, atezolizumab increases the risk of adverse events
in combination with ofatumumab, bamlanivimab increases the risk of adverse events.
in combination with ofatumumab, basiliximab increases the risk of adverse events
in combination with ofatumumab, bebtelovimab increases the risk of adverse events
in combination with ofatumumab, belimumab increases the risk of adverse events.
in combination with ofatumumab, bezlotoxumab increases the risk of adverse events.
in combination with ofatumumab, bimekizumab increases the risk of adverse events.
in combination with ofatumumab, burosumab increases the risk of adverse events.
in combination with ofatumumab, canakinumab increases the risk of adverse events.
in combination with ofatumumab, caplacizumab increases the risk of adverse events.
in combination with ofatumumab, cemiplimab increases the risk of adverse events.
in combination with ofatumumab, cetuximab increases the risk of adverse events.
in combination with ofatumumab, cilgavimab increases the risk of adverse events.
in combination with ofatumumab, denosumab increases the risk of adverse events.
in combination with ofatumumab, dinutuximab increases the risk of adverse events.
in combination with ofatumumab, dostarlimab increases the risk of adverse events.
in combination with ofatumumab, erythropoietin increases the risk of thrombosis.
in combination with ofatumumab, they increase the activity of thrombogenesis.
in combination with ofatumumab, they increase the activity of thrombogenesis.
in combination with ofatumumab, they increase the activity of thrombogenesis.
in combination with ofatumumab, they increase the activity of thrombogenesis.
in combination with ofatumumab, they increase the activity of thrombogenesis
in combination with ofatumumab, fanolesomab increases the risk of adverse events
in combination with ofatumumab, fremanuzumab increases the risk of adverse events
in combination with ofatumumab, galcanezumab increases the risk of adverse events
in combination with ofatumumab, golimumab increases the risk of adverse events
in combination with ofatumumab, guselkumab increases the risk of adverse events
in combination with ofatumumab, IgG increases the risk of adverse events
in combination with ofatumumab, ibalizumab increases the risk of adverse events
in combination with ofatumumab, imlifidase decreases its therapeutic efficacy
in combination with ofatumumab, inebilizumab increases the risk of adverse events
in combination with ofatumumab, infliximab increases the risk of adverse events
in combination with ofatumumab, inotuzumab ozogamicin increases the risk of adverse events
in combination with ofatumumab, isatuximab increases the risk of adverse events
in combination with ofatumumab, isatuximab increases the risk of adverse events
in combination with ofatumumab, lanadelumab increases the risk of adverse events
in combination with ofatumumab, loncastuximab tesirine increases the risk of adverse events
in combination with ofatumumab, maftivimab increases the risk of adverse events
in combination with ofatumumab, mepolizumab increases the risk of adverse events
in combination with ofatumumab, mogamulizumab increases the risk of adverse events
in combination with ofatumumab, muromonab increases the risk of adverse events
in combination with ofatumumab, natalizumab increases the risk of adverse events
in combination with ofatumumab, necitumumab increases the risk of adverse events
in combination with ofatumumab, nivolumab increases the risk of adverse events
in combination with ofatumumab, obiltoxaximab increases the risk of adverse events
in combination with ofatumumab, obinutuzumab increases the risk of adverse events
in combination with ofatumumab, ocrelizumab increases the risk of adverse events
in combination with ofatumumab, odesivimab increases the risk of adverse events
in combination with ofatumumab, olaratumab increases the risk of adverse events
in combination with ofatumumab, omalizumab increases the risk of adverse events
in combination with ofatumumab, palivizumab increases the risk of adverse events
in combination with ofatumumab, panitumumab increases the risk of adverse events
in combination with ofatumumab, peginesatide increases the risk of adverse events
in combination with ofatumumab, pembrolizumab increases the risk of adverse events
in combination with ofatumumab, pertuzumab increases the risk of adverse events
in combination with ofatumumab, raxibacumab increases the risk of adverse events
in combination with ofatumumab, reslizumab increases the risk of adverse events
in combination with ofatumumab, rituximab increases the risk of adverse events
in combination with ofatumumab, sarilumab increases the risk of adverse events
in combination with ofatumumab, siltuximab increases the risk of adverse events
in combination with ofatumumab, sutimlimab increases the risk of adverse events
in combination with ofatumumab, tezepelumab increases the risk of adverse events
tibolone increases the thrombogenic activity of ofatumumab.
in combination with ofatumumab, tildrakizumab increases the risk of adverse events
in combination with ofatumumab, tixagevimab increases the risk of adverse events.
in combination with ofatumumab, tocilizumab increases the risk of adverse events
in combination with ofatumumab, tralokinumab increases the risk of adverse events
in combination with ofatumumab, trastuzumab increases the risk of adverse events
in combination with ofatumumab, ustekinumab increases the risk of adverse events
in combination with ofatumumab, vedolizumab increases the risk of adverse events
may enhance the immunosuppressive effect of immunosuppressants
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
may have an increased immunosuppressive effect when combined with ofatumumab
may have an increased immunosuppressive effect when combined with ofatumumab
may have an increased immunosuppressive effect when combined with ofatumumab
may have an increased immunosuppressive effect when combined with ofatumumab
may have an increased immunosuppressive effect when combined with ofatumumab
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
ofatumumab: they may increase the immunosuppressive effect of immunostimulants
ofatumumab: they may increase the immunosuppressive effect of immunostimulants
ofatumumab: they may increase the immunosuppressive effect of immunostimulants
ofatumumab: they may increase the immunosuppressive effect of immunostimulants
ofatumumab: they may increase the immunosuppressive effect of immunostimulants
ofatumumab: they may increase the immunosuppressive effect of selective immunosuppressants
ofatumumab: they may increase the immunosuppressive effect of selective immunosuppressants
ofatumumab: they may increase the immunosuppressive effect of selective immunosuppressants
may enhance immunosuppressive effects of methotrexate
combination may enhance the immunosuppressive effect and lead to serious infections
corticosteroids increase the effect of immunosuppression of ofatumumab
may increase the immunosuppressive effect of immunosuppressant
may increase the risk of adverse effects when combined
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
may increase the adverse effect of Immunosuppressants
Actions and Spectrum:
ofatumumab is a monoclonal antibody used to treat certain types of cancer, including chronic lymphocytic leukemia (CLL) and relapsing multiple sclerosis (MS). It works by targeting a protein called CD20, which is found on the surface of B cells. By binding to CD20, ofatumumab can trigger the destruction of B cells, which can help to slow the progression of cancer or MS.
The actions of ofatumumab include:
The spectrum of ofatumumab’s activity includes targeting B cells that express CD20. It is mainly used in treating CLL, but it has also been approved for use in relapsing MS. ofatumumab is generally well-tolerated. However, it can cause side effects such as infusion reactions, infections, and low blood cell counts.
Adverse drug reactions:Â Â
Frequency defined:Â Â
>10%Â
Upper respiratory tract infections
Bronchitis
Nausea
Rash
Dyspnea
Fatigue
Anemia
Diarrhea
Cough
Pyrexia
Pneumonia
Neutropenia
<10%:
Intestinal obstruction
Hepatitis B reactivation
Progressive multifocal leukoencephalopathy
Infection (sepsis, pneumonia)
Cytopenia
Infusion complication/reaction
Black Box Warning:
It’s important to note that the information provided is not related to obinutuzumab but to CD20-directed cytolytic antibodies in general, including ofatumumab. Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain viral infection that can occur in patients receiving CD20-directed cytolytic antibodies. It includes ofatumumab and other similar medications, such as rituximab and obinutuzumab. PML can be fatal, and there is no known effective treatment for the condition.
Hepatitis B virus (HBV) reactivation is another potential complication that can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab. In some cases, this can result in severe liver damage or even death. Before starting treatment with ofatumumab, all patients should be screened for HBV infection. If a patient is positive for HBV, they should be closely monitored during and after treatment, and the medication should be stopped if there are signs of reactivation.
Contraindication/Caution:
The following are some contraindications and precautions to be aware of when considering the use of ofatumumab:
Pregnancy Â
Category C: No adequate evidence for a result in humans must take care of potential risks in pregnant women. Usage with caution is advised if the benefits outweigh the risks.Â
 Breastfeeding warnings:   Â
The published studies show no evidence of neonates or infants ingesting the maternal antibodies secreted in breast milk. However, still, it is not advised to breastfeed during treatment with ofatumumab.Â
Pregnancy Categories:     Â
Pharmacology
ofatumumab is a monoclonal antibody used to treat certain types of cancers and autoimmune disorders. It works by targeting and binding to a protein called CD20 that is found on the surface of certain types of immune cells.
When ofatumumab binds to CD20, it triggers a series of immune responses that lead to the destruction of the targeted cells. Specifically, ofatumumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to eliminate the CD20-positive cells.
Pharmacodynamics:
When ofatumumab binds to CD20, it induces a series of immune responses that lead to the destruction of the targeted B-cells through two main mechanisms:
Pharmacokinetics:
Pharmacokinetics studies how a drug is absorbed, distributed, metabolized, and eliminated by the body. The following parameters can describe the pharmacokinetics of ofatumumab.
Absorption
ofatumumab is administered intravenously and is rapidly and completely distributed throughout the bloodstream.
Distribution
ofatumumab has a high volume of distribution, indicating that it is distributed widely throughout the body. The drug binds specifically to CD20-positive B-cells and does not appear to bind to other cells or tissues
Metabolism
ofatumumab is a large protein molecule that is not metabolized by the body. It is broken down into small peptides and amino acids, which are eliminated through normal metabolic pathways.
Elimination and excretion
The elimination half-life of ofatumumab is approximately 15-20 days, indicating that it is cleared from the body relatively slowly. The drug is primarily eliminated through catabolism and proteolysis, and the elimination rate is not significantly affected by renal or hepatic function.
Administration:
ofatumumab is typically administered as an intravenous infusion in a healthcare setting, such as a hospital, clinic, or infusion center.
The compatible solutions for IV infusion are 0.9% NaCl. Prepare the dose in 1000 ml of polyolefin bag containing 0.9% NaCl.
Patient information leaflet
Generic Name: ofatumumab
Pronounced: OH-fa-TOO-mue-mab
Why do we use ofatumumab?
ofatumumab is approved for use in the treatment of:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
